Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhaled ZYESAMI™ for the Treatment of Severe COVID-19

NCT04360096 is registered in ClinicalTrials.gov with APR Applied Pharma Research s.a. as lead sponsor.

NCT NCT04360096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04360096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inhaled ZYESAMI™ for the Treatment of Severe COVID-19
Lead sponsor
APR Applied Pharma Research s.a.
Phase
Phase 2/3
Overall status
Terminated
Start date
February 15, 2021
Completion date
December 31, 2021
Enrollment
144 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute lung injury/acute respiratory distress syndrome (ards), ali, ards, covid, dyspnea, sars-cov 2